Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine + Standard Therapy for Chronic GVHD
NCT00031824Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2002
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Hydroxychloroquine + SOC with Placebo + SOC (2 arms). Primary endpoint: Progression Free Survival. Started Apr 2002; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00031824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031824.